TransMedics Group (NASDAQ:TMDX) Price Target Raised to $125.00

TransMedics Group (NASDAQ:TMDX) had its price objective increased by Oppenheimer from $105.00 to $125.00 in a research note published on Wednesday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Other analysts also recently issued reports about the company. JPMorgan Chase & Co. lifted their price target on TransMedics Group from $87.00 to $105.00 and gave the stock an overweight rating in a report on Tuesday, February 27th. Morgan Stanley boosted their target price on TransMedics Group from $75.00 to $95.00 and gave the stock an equal weight rating in a research note on Wednesday, February 28th. Finally, Piper Sandler started coverage on shares of TransMedics Group in a research note on Thursday, March 28th. They issued an overweight rating and a $95.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average target price of $119.00.

TransMedics Group Stock Up 2.9 %

TMDX stock opened at $127.99 on Wednesday. The company’s 50 day moving average price is $85.54 and its 200 day moving average price is $76.85. The firm has a market capitalization of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $129.66. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. The company had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The company’s quarterly revenue was up 132.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.08) EPS. On average, equities research analysts anticipate that TransMedics Group will post -0.14 EPS for the current fiscal year.

Insider Activity

In other TransMedics Group news, insider Tamer I. Khayal sold 63,260 shares of TransMedics Group stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the transaction, the insider now owns 9,792 shares of the company’s stock, valued at $1,062,823.68. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, insider Tamer I. Khayal sold 63,260 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the completion of the sale, the insider now owns 9,792 shares in the company, valued at approximately $1,062,823.68. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 736 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the transaction, the insider now directly owns 14,375 shares in the company, valued at $1,295,043.75. The disclosure for this sale can be found here. In the last three months, insiders sold 236,378 shares of company stock valued at $23,633,449. Insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of TransMedics Group by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock valued at $99,341,000 after purchasing an additional 29,798 shares during the last quarter. Moody Aldrich Partners LLC increased its stake in TransMedics Group by 110.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company’s stock valued at $3,655,000 after buying an additional 24,290 shares during the period. American Century Companies Inc. raised its position in TransMedics Group by 271.2% during the 3rd quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock worth $26,661,000 after buying an additional 355,755 shares during the last quarter. Eagle Health Investments LP lifted its stake in shares of TransMedics Group by 78.5% in the 3rd quarter. Eagle Health Investments LP now owns 414,205 shares of the company’s stock worth $22,678,000 after acquiring an additional 182,173 shares during the period. Finally, Qube Research & Technologies Ltd boosted its holdings in shares of TransMedics Group by 31.2% in the third quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock valued at $4,624,000 after acquiring an additional 20,081 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.